Differential diagnosis of thymic carcinoma and lung carcinoma with the use of antibodies to cytokeratins  by Fukai, Ichiro et al.
GENERAL THORACIC SURGERY 
DIFFERENTIAL DIAGNOSIS 
OF THYMIC CARCINOMA 
AND LUNG CARCINOMA 
WITH THE USE OF 
ANTIBODIES TO 
CYTOKERATINS 
There are few specific pathologic findings that Can be relied on to 
distinguish primary thymic carcinomas from lung carcinomas with medi- 
astinal extension or showing metastasis to the anterior mediastinum. The 
immunohistochemical reactivity on frozen sections of thymic carcinomas 
and lung carcinomas, which are histologically similar to each other, was 
examined with the use of monoclonal antibodies to cytokeratins 7 and 13. 
Among keratinizing squamous cell carcinomas, all thymic carcinomas 
reacted with antibody specific for cytokeratin 7 (9/9, 100%), whereas no 
staining reaction was seen in lung carcinomas (0/5, 0%) (p < 0.01). This 
finding can be used as a diagnostic aid in primary thymic keratinizing 
squamous cell carcinomas to expedite treatment and prognosis. Cytokera- 
tin 7 and cytokeratin 13 monoclonal antibodies reacted with almost all 
cases of thymic carcinoma. Applications of monoclonal antibodies specific 
for certain cytokeratins, especially 7 and 13, may be helpful in the diagnosis 
of other subtypes of thymic carcinomas. (J THORA¢ CARDIOVASC SURG 1995; 
110:1670-5) 
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B ecause of their relative rarity and close histologic similarity to lung carcinomas, primary thymic 
carcinomas might be misdiagnosed as lung carcino- 
mas involving the mediastinum. Among the wide 
variety of morphologic appearances, quamous cell 
carcinoma (SCC) represents a common type of 
thymic carcinoma. Therefore it is important to 
differentiate thymic SCC from lung SCC with medi- 
astinal extension, because the former appears to 
have a better prognosis in some instances, when 
properly treated)'  2 
Cytokeratins are a complex group of substances 
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comprising at least 19 different polypeptides, which 
range in molecular weight from 49,000 to 68,000 
daltons. There are different combinations of cyto- 
keratins in epithelial cells, depending on the cell 
type, and epithelium-derived tumors maintain the 
expression of some of the cytokeratin p01ypeptides 
typical of the specific nontransformed cells. 3' 4 We 
prevlously reported that human thymic epithelial 
cells could be subdivided in terms of their expres- 
sion of cytokeratin. 5 A given thymic carcinoma can 
therefore be distinguished from a lung carcinoma, if
the combination of cytokeratin polypeptides in thy- 
mic tissue is different from that in bronchial tissue. 
The present study was undertaken to determine 
whether some cytokeratins not expreSsed in lung Car- 
cinomas may, in fact, be present in thymic carcinomas. 
Material and methods 
Tissues. Between 1984 and 1993, samples from 98 cases 
of thymic epithelial tumors were collected from various 
hospitals in Japan. Among the samples, 17 Were identified 
as thymic carcinomas histologically. The cases in the 
present study were those of cytologically malignant epi- 
thelial tumors located in the anterior mediastinum. This 
criterion for selection included the absence of a primary 
tumor at sites other than the anterior mediastinum atthe 
1670 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 110, Number 6 
Fukai et al. 1671 
time of presentation, a' 6 In addition, five biopsy samples of 
normal thymus tissue were collected from children at the 
time of operation for funnel chest after parental consent 
was obtained. 
Fresh specimens of tumors and normal thymus tissue 
were snap-frozen i Optimum Cutting Temperature me- 
dium (Bayer Corp., Elkhart, Ind.) and stored at -75°C 
for immunopero~dase staining. Portions of the specimens 
fixed in 10% formalin were embedded in paraffin for 
routine histologic studies. 
Mouse monoclonal antibodies. Two mouse monoclona! 
antibodies were used in this study. The first, RCK105 
( immunog lobu l in  G1) ,  7 in immunoblotting reacts only 
with single cytokeratin polypeptide cytokeratin 7 and 
stains a subgroup of glandular epithelia nd their tumors, 
next to transitional b adder epithelium and bladder carci- 
nomas. The second, 2D7 (immunoglobulin G2b), 8 recog- 
nizes only cytokeratin 13 in immunoblotfing studies and 
reacts with noncornifying squamous epithelia. Both were 
purchased from ICN Corporation (Lisle, Ind.). Neither 
RCK105 nor 2D7 is applicable for formaldehyde-fixed 
paraffin-embedded tissues. 
Staining procedure. Serial sections, 4 ~m thick, were 
fixed in acetone at 4 ° C for 10 minutes, air dried, washed 
in phosphate-buffered saline solution (pH 7.2), treated 
with 5 mmol/L periodic acid for 10 minutes at room 
temperature to remove ndogenous peroxidase activity, 9 
and reacted with primary mouse monoclonal antibodies 
for 60 minutes at room temperature. The sections were 
stained by the streptavidin-bi0tin-per0xidase complex 
method with the His tofine kit (Nichirei, Tokyo, Japan). 
RCK105 and 2D7 were applied at a dilution of 1:10. The 
sections reacted in a solution consisting of 20 mg of 
3,3'-diaminobenzidine-4HC1 in 100 ml of 0.005 mol/L Tris 
HC1 buffer (pH 7.6) containing hydrogen peroxide 
0.005%; this reaction was complete in 10 minutes. Next, 
the sections were washed in phosphate-buffered saline 
solution, counterstained with methyl green, dehydrated in 
a graded alcohol series and xylene, and mounted with 
synthetic resin. For negative control specimens, phos- 
phate:buffered saline solution and normal mouse serum 
(1:10 dilution) were used instead of the primary mouse 
monoclonal ntibodies. 
Results 
ThYmus. The localization of epithelium express- 
ing cytokeratin 7 and cytokeratin 13 is shown in 
Table I. The monoclonal antibody 2D7, which is 
specific for cytokeratin 13, labeled some subcapsu- 
lar-cortical epithelia! subsets and medullary epithe- 
lium except for a minor cell subset localized near the 
cortex. The monoclonal antibody RCK105, which is 
specific for cytokeratin 7, labeled a somewhat 
smaller number of subcapsular-cortical and medul- 
lary epithelial cells than 2D7 (Fig. 1). 
Tumors. Seventeen thymic carcinomas were clas- 
sified according to the published criteria 2 into nine 
well-differentiated (keratinizing) SCCs, five lympho- 
epithelioma-like carcinomas, two undifferentiated 
Table I. Localization of cytokeratins 7and 13 in 
epithelial cells in normal thymus 
Cortex Medulla 
No. of 
cytokeratins* Subcapsular Intracortical Periphery Inner 
CK7 - - + - - _+ 
CK13 ± - - + 
C/< cytokeratin; - - -+ ,  rare cells; - ,  negative; +-, multiple positive cells; 
+, majority of positive cells. 
*Moll's classification. 
carcinomas, and 1 mucoepidermoid carcinoma. 
Morphologically, well-differentiated (keratinizing) 
SCCs by published criteria appear to correspond to 
well-differentiated to moderately differentiated pup 
monary SCCs of lung origin. Five cases of well- 
differentiated to moderately differentiated pulmo- 
nary SCCs were also studied. For the sake of 
convenience, we here use the term keratinizing SCCs 
for both thymic well-differentiated (keratinizing) 
SCCs and we!l-differentiated to moderately differ- 
entiated pulmonary SCCs. 
Cytokeratin 7 and cytokeratin 13 expression in 
thymic carcinomas and lung carcinomas i summa- 
rized in Table II. Among keratinizing SCCs, all 
thymic carcinomas reacted with RCK105 (9/9, 
100%), whereas no staining reaction was seen in 
lung carcinomas (p < 0.01) (Fig. 2). The monoclonal 
antibody 2D7 reacted with all cases of thymic lym- 
phoepithelioma,like carcinoma (Fig. 3). Both 
RCK105 and 2D7 reacted with undifferentiated 
carcinomas and mucoepidermoid carcinoma of thy- 
mic origin. 
Discussion 
In any case in which thymic carcinoma is considered 
to be the diagnosis, exhaustive clinical investigation 
to rule out a primary extrathymic neoplasm is re- 
quired, because there are few specific pathologic 
findings that can be relied on to distinguish primary 
thymic carcinomas from the metastatic neoplasms 
that are so histologically similar. 6However, in some 
instances, it might be impossible to differentiate 
thymic arcinoma from lung carcinoma involving the 
mediastinum or showing metastasis to the anterior 
mediastinum. 
Thymic carcinomas can be subclassified into cat- 
egories including well-differentiated (keratinizing) 
SCC, lymphoepithelioma-like carcinoma, small cell 
carcinoma, sarcomatoid carcinoma, clear cell carci- 
noma, mucoepidermoid carcinoma, basaloid carci- 
noma, and undifferentiated carcinoma. Of these, 
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Fig. 1. Double immunolabeling of normal human thymus tissue with RCK105 and 2D7 (mirror sections). 
A, RCK105 (original magnification ×20). B, 2D7 (original magnification ×20). RCK105 labeled somewhat 
smaller number of medullary epithelial cells than 2D7. 
well-differentiated (keratinizing) SCC and lympho- 
epithelioma-like carcinoma represent therelatively 
frequent ypes. 2 Morphologically, thymic well-dif- 
ferentiated (keratinizing) SCCs appear to corre- 
spond to pulmonary well-differentiated to moder- 
ately differentiated SCCs, that is, keratinizing SCCs, 
and lymphoepithelioma-like carcinoma is a unique 
morphotype that is only rarely seen in primary 
tumors of the lung. 1° Therefore it is desirable to 
differentiate keratinizing SCCs of thymic origin 
from those of lung origin with mediastinal extension 
or showing metastasis to the anterior mediastinum. 
The former appears to have a better prognosis, if 
properly treated, l' 2 
With the use of monoclonal antibodies specific for 
a single cytokeratin, we earlier reported that thymic 
epithelial cells could be subdivided in terms of their 
cytokeratin expression and found that discrete reed- 
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Fig. 2. Hematoxylin and eosin-stained sections of hymic keratinizing SCC (A) and pulmonary keratin- 
izing SCC (B) (original magnification ×80). Cytokeratin 7 antibody RCK105 shows completely positive 
reaction in thymic keratinizing SCC (C), but does not react with pulmonary keratinizing SCC (D) (original 
magnification ×80). 
Table II. Expression of cytokeratins in thymic carcinomas and lung carcinomas 
Origin. CK7 CK13 
Keratinizing SCCs 
Lymphoepithelioma-like carcinoma 
Undifferentiated carcinomas 
Mucoepidermoid carcinoma 
Thymus 9/9 (100%) 1, 8/9 (88.9%) 
Lung 0/5 (0%) 1 4/5 (80%) 
Thymus 3/5 (60%) 5/5 (100%) 
Thymus 2/2 (100%) 2/2 (100%) 
Thymus 1/1 (100%) 1/1 (100%) 
*p < 0.01. 
ullaly epithelial subsets located near the Hassall's 
corpuscles expressed cytokeratin 18 and the major- 
ity of the epithelial ceils of thymic carcinoma ex- 
pressed cytokeratin 18. 5 Immunohistochemical anal- 
ysis by Broers and colleagues 11indicated that the 
presence of cytokeratin 7, normally occurring in 
lung adenocarcinomas, varied in lung SCC from 
no positive cells in well-differentiated SCCs to a 
positive reaction in all tumor cells for poorly 
differentiated SCCs. They suggested the presence 
of varying degrees of adenocarcinoma differenti- 
ation within SCCs, whereas in lung SCCs histo- 
logic squamous cell differentiation has been found 
in parallel with the presence of cytokeratin 13.11 
Cytokeratin 13 antibody thus reacts with many 
more cases and many more cells of keratinizing 
SCC as compared with its reaction in poorly 
differentiated SCC. All keratinizing SCCs of thy- 
mic origin reacted with RCK105 (cytokeratin 7) in 
the present study, whereas no staining reaction 
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Fig. 3. A, Hematoxylin and eosin-stained section of lymphoepithelioma-like thymic carcinoma (original 
magnification ×80). B, Large areas of this tumor a e stained with cytokeratin 13 a tibody 2D7 (original 
magnification xS0). 
was seen in those of lung origin. This result is 
highly indicative of the possibility of differential 
diagnosis between thymic keratinizing SCCs and 
lung keratinizing SCCs. 
Broers and colleagues 11indicated the possibility 
of limited focal reaction with cytokeratin 7 antibody 
RCK105 in lung keratinizing SCCs because of tu- 
mor heterogeneity. However, thymic carcinomas, 
which probably originate in thymic medullary epi- 
thelium, 5 would ordinarily tend to exhibit much 
larger quantities of cytokeratin 7 positive cells in 
cases of keratinizing SCC than would be seen in lung 
SCCs. 
In conclusion, we believe that establishing the 
value of immunolabeling for cytokeratin 7 in the 
diagnosis of primary thymic keratinizing SCCs may 
have a decidedly favorable impact on treatment and 
prognosis. Because both RCK105 (cytokeratin 7)
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and 2D7 (cytokeratin 13) reacted in almost all cases 
of  thymic carcinoma, the possibility exists that other 
subtypes of thymic carcinomas comparable to those 
seen in lung, nasopharynx (lymphoepithelioma), 
kidney, and salivary gland 6 may be differentiated 
from metastasis to the anterior mediastinmn from a 
tumor in those sites by the use of monoclonal 
antibodies pecific for certain cytokeratins especially 
cytokeratins 7 and 13. 
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